4 Healthcare Stock Stories Creating a Thursday Buzz

Isis Pharmaceuticals (NASDAQ:ISIS): Closing price $21.66

On Thursday, Isis announced that it earned a $6-million payment from AstraZeneca linked with a continuation of the research collaboration aimed at discovering and developing novel antisense therapeutics for the treatment of cancer. Alongside the research collaboration, which includes three cancer targets, the firms are developing two antisense drugs, ISIS-AR and ISIS-STAT, discovered by Isis and licensed to AstraZeneca to treat cancer.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ISIS

Rosetta Genomics (NASDAQ:ROSG): Closing price $3.89

Rosetta said that a manuscript reporting data validating the clinical usefulness of the Rosetta Cancer Origin Test to identify the tumor of origin in Cancer of Unknown or Uncertain Primary, has been accepted for publication in the peer-reviewed on-line journal Molecular Cancer. The article demonstrates a 92-percent agreement with diagnosis based on clinicopathologic and management data, in a cohort of patients with carcinoma of unknown primary. It marks the seventh peer-reviewed publication relating to the firm’s CUP assays, and the fifth peer-reviewed publication relating to post market validation studies showing the Cancer Origin Test’s ability to identify tumor origin in CUP with 92-percent concordance, the highest level of accuracy of any like study published thus far.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ROSG

Regeneron Pharmaceuticals (NASDAQ:REGN): Closing price $252.17

Regeneron and Bayer HealthCare on Thursday reported positive top-line results for Eyea (aflibercept) Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization. In this trial, patients receiving Eylea at an initial dose of 2 milligrams, followed by treatment on an as-needed  basis, exhibited a mean improvement in best-corrected visual acuity from baseline at week 24 of 12.1 letters, compared to a loss of 2 letters in patients receiving sham injections.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

REGN

Alexion Pharmaceuticals (NASDAQ:ALXN): Closing price $92.90

Alexion announced that data published in the June 6th issue of The New England Journal of Medicine show that chronic Soliris (eculizumab) therapy is effective in the treatment of patients suffering from atypical hemolytic uremic syndrome, which is a genetic, life-long, and extremely rare disease linked with vital organ failure and premature death. In patients having aHUS, uncontrolled terminal complement activation leads to thrombotic microangiopathy, the formation of blood clots in small blood vessels throughout the body.

Are these stocks a buy or sell? Let us help you decide. Check out our Stock Picker Newsletter now.

ALXN

Don’t Miss: Is Kathleen Sebelius Soliciting For More Obamacare Funding?